![Anabella Villalobos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 58 500 $ in data 30/06/2026
Anabella Villalobos currently works at Coya Therapeutics, Inc., as Independent Director from 2021.
Dr. Villalobos also formerly worked at Biogen, Inc., as SVP-Biotherapeutics & Medicinal Sciences from 2017 to 2025 and Pfizer Inc., as Vice President from 1989 to 2017.
Dr. Villalobos received her doctorate degree from the University of Kansas and undergraduate degree from the University of Panama.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/05/2026 | 10.000 ( 0,04% ) | 58 500 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COYA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 25/05/2021 |
| Società | Posizione | Fine |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2025 |
| PFIZER INC. | Corporate Officer/Principal | 01/01/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Panama
 University of Panama Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coya Therapeutics, Inc.
 Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
